Get the Stockscreener App
14.73
0.14%
0.02
Pre-market:
15.50
0.77
+5.23%
Jade Biosciences Inc stock is traded at $14.73, with a volume of 1.05M.
It is up +0.14% in the last 24 hours and down -30.94% over the past month.
Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.
See More
Previous Close:
$14.71
Open:
$14.59
24h Volume:
1.05M
Relative Volume:
1.10
Market Cap:
$936.79M
Revenue:
-
Net Income/Loss:
$-129.61M
P/E Ratio:
-4.9312
EPS:
-2.9871
Net Cash Flow:
$-116.59M
1W Performance:
-14.06%
1M Performance:
-30.94%
6M Performance:
+11.09%
1Y Performance:
+81.40%
1-Day Range:
$14.45
$15.06
1-Week Range:
$14.45
$17.67
52-Week Range:
$7.6944
$28.00
Jade Biosciences Inc Stock (JBIO) Company Profile
Name
Jade Biosciences Inc
Sector
Industry
Phone
(781) 312-3013
Address
221 CRESCENT ST., WALTHAM
Compare JBIO vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JBIO
Jade Biosciences Inc
|
14.73 | 936.79M | 0 | -129.61M | -116.59M | -2.9871 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Jade Biosciences Inc Stock (JBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Initiated | H.C. Wainwright | Buy |
| Oct-09-25 | Initiated | BTIG Research | Buy |
| Jul-14-25 | Initiated | Jefferies | Buy |
| Jun-16-25 | Upgrade | Guggenheim | Neutral → Buy |
| May-07-25 | Initiated | Wedbush | Outperform |
| May-05-25 | Initiated | Stifel | Buy |
| May-02-25 | Initiated | TD Cowen | Buy |
| Jun-18-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Jun-18-24 | Downgrade | TD Cowen | Buy → Hold |
| Jun-18-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-17-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jun-17-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-17-24 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-25-24 | Resumed | Jefferies | Buy |
| Dec-08-23 | Initiated | Wells Fargo | Equal Weight |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Dec-06-22 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-19-22 | Resumed | Wedbush | Outperform |
| Aug-16-22 | Downgrade | BTIG Research | Buy → Neutral |
| Feb-11-22 | Initiated | BTIG Research | Buy |
| Jul-26-21 | Initiated | Cowen | Outperform |
| Jul-26-21 | Initiated | Evercore ISI | Outperform |
| Jul-26-21 | Initiated | Jefferies | Buy |
| Jul-26-21 | Initiated | Wedbush | Outperform |
View All
Jade Biosciences Inc Stock (JBIO) Latest News
Jade Biosciences at stifel 2026 virtual immunology and inflammation forum: pipeline push - Investing.com Canada
JBIO: JADE101 leads a robust pipeline with best-in-class data and rapid path to market in IgA nephropathy - TradingView
Jade Biosciences at citigroup summit: fast-track bet on igan By Investing.com - Investing.com India
Jade Biosciences at Wells Fargo conference: pipeline bets on JADE 101 By Investing.com - Investing.com South Africa
Jade Biosciences at Wells Fargo conference: pipeline bets on JADE 101 - Investing.com
Jade Biosciences Company Profile & Introduction - moomoo.com
JADE BIOSCIENCES, INC. : CLEAR STREET RAISES TARGET PRICE TO $48 FROM $25 - moomoo.com
symbol__ Stock Quote Price and Forecast - CNN
Clear Street Maintains Jade Biosciences(JBIO.US) With Buy Rating, Raises Target Price to $48 - moomoo.com
LifeSci Capital Maintains Jade Biosciences(JBIO.US) With Buy Rating, Maintains Target Price $42 - Moomoo
Jade Biosciences to Participate in Upcoming Conferences - Yahoo Finance
Jade Biosciences (JBIO) Slips 1.6% as Shares Test Key Support at $19.97Median Line - dars.gov.et
Jade (JBIO) Financial Update: The Bottom-Line Figure Trails Its Comparison in the Latest Session; Investor Response: Shares End With Little Net Change at the CloseEarnings Season Outlook - dars.gov.et
Bio Ionic Partners with Ulta Beauty on Limited Edition Jade Dream Collection - Yahoo Finance
Jade Biosciences (NASDAQ:JBIO) Shares Gap UpWhat's Next? - MarketBeat
Jade Biosciences advances JADE101 for IgAN with promising Phase 1 results and Phase 2 data due in 2027 - Pluang
Jade Biosciences: Duration Is The Real Product (NASDAQ:JBIO) - Seeking Alpha
Jade Biosciences (JBIO) Stock Analysis Report | Financials & Insights - Benzinga España
H.C. Wainwright Maintains Jade Biosciences(JBIO.US) With Buy Rating, Maintains Target Price $55 - Moomoo
Stifel Maintains Jade Biosciences(JBIO.US) With Buy Rating, Maintains Target Price $40 - Moomoo
HC Wainwright Analysts Increase Earnings Estimates for JBIO - MarketBeat
Jade Biosciences (JBIO) Shares Just Moved, So What Is Going On? - Sahm
Jade Biosciences (JBIO) Advances 2.4% to $22.89 as Buyers Defend Key Support ZoneFlat Correction - vinanet.vn
Renaissance Technologies LLC Boosts Holdings in Jade Biosciences, Inc. $JBIO - MarketBeat
Jefferies Maintains Jade Biosciences(JBIO.US) With Buy Rating, Raises Target Price to $48 - Moomoo
Analysts Offer Insights on Healthcare Companies: Jade Biosciences (JBIO), Silence Therapeutics (SLN) and Vertex Pharmaceuticals (VRTX) - theglobeandmail.com
Wedbush Maintains Jade Biosciences(JBIO.US) With Buy Rating, Announces Target Price $47 - Moomoo
A Quick Look at Today's Ratings for Jade Biosciences(JBIO.US), With a Forecast Between $42 to $77 - Moomoo
Jade Biosciences Is Maintained at Buy by BTIG - Moomoo
Jade Biosciences (NASDAQ:JBIO) Given New $77.00 Price Target at BTIG Research - MarketBeat
Jade Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
JBIO Q1 2026 Earnings: Wider Loss Highlights Clinical-Stage Investment CycleEarnings Growth Analysis - careplusvn.com
JBIO SWOT Analysis: Financial Challenges and Development Opportu - GuruFocus
Jade Biosciences, Inc. Stock 12‑Month Price Target Raised to $46.44, Implies 111% Upside - TradingView
Wedbush raises Jade Biosciences price target on pipeline progress By Investing.com - Investing.com Australia
Wedbush raises Jade Biosciences price target on pipeline progress - Investing.com
Jade Biosciences Releases Q2 2026 Financial Results - AlphaStreet
Jade Biosciences Announces Q2 2026 Financial Results Highlighting Increased R&D and Asset Growth - Kalkine Media
Jade Biosciences Q2 Results: EPS Misses Estimate, Losses Widen - scanx.trade
Jade Biosciences' Q2 Loss Narrows - marketscreener.com
Earnings Flash (JBIO) Jade Biosciences Posts Q2 Loss $0.76 a Share, vs. FactSet Est of $0.63 Loss - marketscreener.com
Jade Biosciences reports Q2 net loss $55.8M, cash $461.2M; advances JADE101 to Phase 2/3 - TradingView
Jade Biosciences (NASDAQ: JBIO) boosts cash to $461M while loss widens - Stock Titan
Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Jade Biosciences reports $55.8 million Q2 net loss - Quiver Quantitative
Jade Biosciences Q2 net loss widens as costs rise - TradingView
Jade Biosciences Inc expected to post a loss of 64 cents a shareEarnings Preview - TradingView
Jade Biosciences, Inc. (NASDAQ:JBIO) Receives Consensus Recommendation of "Moderate Buy" from Analysts - marketbeat.com
Jade Biosciences (NASDAQ:JBIO) Trading 10% HigherHere's What Happened - marketbeat.com
Jade Biosciences (NASDAQ:JBIO) Shares Down 4.2%Here's What Happened - MarketBeat
Orbimed Advisors LLC Sells 346,152 Shares of Jade Biosciences, Inc. $JBIO - MarketBeat
Jade Biosciences Inc Stock (JBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):